tiprankstipranks
Advertisement
Advertisement
Travere Therapeutics announces retirement of Chief Research Officer in 2027
PremiumThe FlyTravere Therapeutics announces retirement of Chief Research Officer in 2027
26d ago
Travere Therapeutics price target raised to $70 from $62 at Citi
Premium
The Fly
Travere Therapeutics price target raised to $70 from $62 at Citi
27d ago
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
Premium
Market NewsSponsored
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
30d ago
Travere Therapeutics enters into exclusive licensing agreement with Everest
PremiumThe FlyTravere Therapeutics enters into exclusive licensing agreement with Everest
1M ago
Travere Licenses Civorebrutinib, Expands Kidney Disease Pipeline
Premium
Company Announcements
Travere Licenses Civorebrutinib, Expands Kidney Disease Pipeline
1M ago
Ligand price target raised to $266 from $263 at BofA
Premium
The Fly
Ligand price target raised to $266 from $263 at BofA
1M ago
Travere Therapeutics Rides FILSPARI Surge After FDA Win
PremiumCompany AnnouncementsTravere Therapeutics Rides FILSPARI Surge After FDA Win
2M ago
Travere Therapeutics Issues New Convertible Notes to Refinance Debt
Premium
Company Announcements
Travere Therapeutics Issues New Convertible Notes to Refinance Debt
2M ago
Travere Therapeutics announces $400M convertible senior notes offering
Premium
The Fly
Travere Therapeutics announces $400M convertible senior notes offering
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100